SELLAS Life Sciences Group (NASDAQ:SLS) Releases Earnings Results, Misses Estimates By $0.01 EPS

SELLAS Life Sciences Group (NASDAQ:SLS) issued its earnings results on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01), FiscalAI reports.

SELLAS Life Sciences Group Price Performance

SLS opened at $11.77 on Thursday. SELLAS Life Sciences Group has a 1-year low of $1.39 and a 1-year high of $15.88. The stock has a market cap of $2.31 billion, a P/E ratio of -56.04 and a beta of 2.48. The stock’s 50 day simple moving average is $11.08 and its 200 day simple moving average is $7.29.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in shares of SELLAS Life Sciences Group by 6.2% in the fourth quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock valued at $201,000 after purchasing an additional 3,114 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of SELLAS Life Sciences Group by 13.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock worth $143,000 after purchasing an additional 4,564 shares in the last quarter. Equitable Holdings Inc. raised its position in shares of SELLAS Life Sciences Group by 18.5% during the 4th quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock worth $121,000 after purchasing an additional 5,000 shares during the last quarter. Bank of America Corp DE raised its position in shares of SELLAS Life Sciences Group by 21.9% during the 3rd quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock worth $68,000 after purchasing an additional 7,571 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

Wall Street Analysts Forecast Growth

SLS has been the topic of a number of recent analyst reports. Alliance Global Partners reaffirmed a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and a consensus price target of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.